Cruz reminds investors of the upcoming February 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Kyverna ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). Shareholders who purchased shares of KYTX ...

NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna's initial public ...

So should Kyverna Therapeutics (NASDAQ:KYTX) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends ...

As part of this appointment, Kyverna's current president of research and development, Dominic Borie, will move to a new role as strategic advisor to Chief Executive Officer Warner Biddle and the ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of ...

NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the ...